Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

Jurkat leukemia cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) Akt (3) AMPK (1) Antibiotic (1) Apoptosis (16) Aurora Kinase (1) Autophagy (1) Bacterial (2) Bcr-Abl (1) c-Myc (1) Calcium Channel (1) Caspase (3) CD47 (1) CDK (2) Checkpoint Kinase (Chk) (1) CXCR (2) DGK (2) Dihydroorotate Dehydrogenase (1) Dipeptidyl Peptidase (1) Discoidin Domain Receptor (1) DNA-PK (1) DNA/RNA Synthesis (4) E1/E2/E3 Enzyme (1) Epigenetic Reader Domain (6) ERK (3) Ferroptosis (1) G-quadruplex (1) HDAC (2) Histone Acetyltransferase (1) Histone Methyltransferase (1) HIV (1) HIV Integrase (1) HSP (1) IFNAR (3) Integrin (1) Interleukin Related (4) JAK (2) JNK (1) Keap1-Nrf2 (1) MAP4K (2) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Molecular Glues (2) NF-κB (1) p38 MAPK (1) Parasite (1) PARP (4) PDGFR (1) Phosphatase (1) PI3K (3) PROTACs (9) Reactive Oxygen Species (ROS) (1) RIP kinase (1) Src (2) STAT (3) STING (1) Tim3 (1) VEGFR (1) Wee1 (2)
By Research Areas:	Cancer (39) Infection (3) Inflammation/Immunology (5) Metabolic Disease (1) Neurological Disease (1)

By Targets:

11β-HSD (1)

Akt (3)

AMPK (1)

Antibiotic (1)

Apoptosis (16)

Aurora Kinase (1)

Autophagy (1)

Bacterial (2)

Bcr-Abl (1)

c-Myc (1)

Calcium Channel (1)

Caspase (3)

CD47 (1)

CDK (2)

Checkpoint Kinase (Chk) (1)

CXCR (2)

DGK (2)

Dihydroorotate Dehydrogenase (1)

Dipeptidyl Peptidase (1)

Discoidin Domain Receptor (1)

DNA-PK (1)

DNA/RNA Synthesis (4)

E1/E2/E3 Enzyme (1)

Epigenetic Reader Domain (6)

ERK (3)

Ferroptosis (1)

G-quadruplex (1)

HDAC (2)

Histone Acetyltransferase (1)

Histone Methyltransferase (1)

HIV (1)

HIV Integrase (1)

HSP (1)

IFNAR (3)

Integrin (1)

Interleukin Related (4)

JAK (2)

JNK (1)

Keap1-Nrf2 (1)

MAP4K (2)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

Molecular Glues (2)

NF-κB (1)

p38 MAPK (1)

Parasite (1)

PARP (4)

PDGFR (1)

Phosphatase (1)

PI3K (3)

PROTACs (9)

Reactive Oxygen Species (ROS) (1)

RIP kinase (1)

Src (2)

STAT (3)

STING (1)

Tim3 (1)

VEGFR (1)

Wee1 (2)

By Research Areas:

Cancer (39)

Infection (3)

Inflammation/Immunology (5)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) TREM receptor BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-176244

KI-TOX-A3	Histone Acetyltransferase	Cancer
KI-TOX-A3 is a TOX protein-protein interaction inhibitor that blocks the TOX-KAT7 protein-protein interaction with an IC₅₀ of 0.51 μM. KI-TOX-A3 induces proteasomal degradation of TOX, restores KAT7-mediated H3K14 acetylation, reverses exhaustion of CD8 ⁺ T cells, and inhibits the proliferation of T cell acute lymphoblastic leukemia (T-ALL) cells. KI-TOX-A3 shows promise for use in studies of hematological malignancies such as T-ALL .

HY-N0660

Jujuboside B	Apoptosis PARP Caspase AMPK Autophagy VEGFR Keap1-Nrf2 STING 11β-HSD Ferroptosis PI3K Akt p38 MAPK ERK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .

HY-168654

WEE1 degrader 1	Wee1	Cancer
WEE1 degrader 1 (Compound 10) is a CRBN-dependent molecular glue degrader of WEE1 and casein kinase 1α (CK1α) with sub-2 nM DC₅₀ values for both targets. WEE1 degrader 1 can be used for the research of acute lymphoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, colorectal adenocarcinoma, diffuse large b cell lymphoma .

HY-155175

TIM-3-IN-2	Tim3 IFNAR	Cancer
TIM-3-IN-2 is a TIM-3 inhibitor. TIM-3-IN-2 blocks the interactions of TIM-3 with PtdSer, CEACAM1 and Gal-9, and inhibits the immunosuppressive function of TIM-3. TIM-3-IN-2 restores IFNγ release from peripheral blood mononuclear cells. TIM-3-IN-2 inhibits the proliferation of acute myeloid leukemia cells. TIM-3-IN-2 can be used for the research of acute myeloid leukemia .

HY-149760

PVD-06	PROTACs Phosphatase IFNAR STAT	Cancer
PVD-06 is a selective PROTAC PTPN2 degrader with a DC₅₀ of 217 nM (selectivity index >60-fold over PTP1B). PVD-06 induces PTPN2 degradation via a VHL-, ubiquitin, and proteasome-dependent pathway. PVD-06 can promote T cell activation and amplify IFN-γ-mediated anticancer activity. PVD-06 can be used to further investigate PTPN2 in diseases such as leukemia and melanoma . (Pink: PTPN2 ligand (HY-168691), Black: linker (HY-B0236), Blue: VHL ligand (HY-112078)).

HY-175287

α5β1 integrin agonist-2	Integrin	Cancer
α5β1 integrin agonist-2 (Compound 2) is a selective α5β1 integrin agonist (EC₅₀ = 45.98 nM). α5β1 integrin agonist-2 induces integrin activation. α5β1 integrin agonist-2 is applicable to the research of leukemia .

HY-168022

CAM2602 1 Publications Verification	Aurora Kinase	Cancer
CAM2602 is an orally active Aurora A-TPX2 protein−protein interaction inhibitor with a human K_d of 19 nM for Aurora A. CAM2602 increases the proportion of PH3 positive cells while reducing P-T288 Aurora A levels. CAM2602 arrests tumor xenograft growth in mice. CAM2602 can be used for the research of cancer, such as acute T cell leukemia .

HY-13305

MK-2048	HIV HIV Integrase Apoptosis PARP	Infection
MK-2048 is a HIV-1 and HIV-1 integrase inhibitor. MK-2048 shows selective activity against HTLV-1-infected cells and retained potency against HIV-1 variants. MK-2048 induces apoptosis, inhibits cell growth, reduces proviral loads, and blocks HTLV-1 transmission and immortalization. MK-2048 can be used for the research of HIV-1 infection .

HY-P5640

Tritrpticin	Bacterial Parasite	Infection
Tritrpticin is a porcine-derived antimicrobial peptide with properties such as membrane disruption and hemolysis. Tritrpticin disrupts the cell membranes of bacteria, fungi and Jurkat T cell leukemia cells and induces their death. Tritrpticin also enhances the efficacy of Metronidazole (HY-B0318) against Trichomonas vaginalis, reduces plasma endotoxin and inflammatory cytokine levels, restricts bacterial growth in blood and visceral tissues, decreases the mortality rate of septic shock in rats and enhances the therapeutic effect of ertapenem. Tritrpticin exhibits selective cytotoxicity against Jurkat T cell leukemia cells, while showing low toxicity to normal peripheral blood mononuclear cells and red blood cells, and can serve as a template for antimicrobial peptide design. Tritrpticin can be applied to research related to bacterial infections, fungal infections, trichomoniasis, septic shock and leukemia .

HY-169093

MS41	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
MS41 is a selective *eleven-nineteen leukemia* (ENL)** PROTAC degrader, with DC₅₀s of 3.50 nM (MV4;11), 2.84 nM (SEMK2), 3.03 nM (Jurkat), and 26.58 nM (KASUMI1), respectively. MS41 effectively inhibits the growth of ENL-dependent leukemia cells, induces G1 cell cycle arrest and increases apoptosis. MS41 reduces the chromatin occupancy of ENL-associated transcription elongation machinery, and suppresses oncogenic gene expression and leukemia progression. Red: ENL ligand (HY-169094). Black: linker (HY-W105744). Blue: VHL ligand (HY-112078) .

HY-179234

LD5097	PROTACs RIP kinase Apoptosis Caspase PARP	Cancer
LD5097 is a highly effective and selective PROTAC degrader targeting RIPK1. LD5097 can rapidly and efficiently downregulate RIPK1 and significantly enhance TNFα-mediated apoptosis in Jurkat cells. LD5097 significantly increases the levels of cleaved caspase-3/7 and PARP. LD5097 can be used for the study of acute T-lymphoblastic leukemia .

HY-175281

SJ11646	PROTACs Src Discoidin Domain Receptor Bcr-Abl Apoptosis	Cancer
SJ11646 is a Dasatinib (HY-10181)-based LCK PROTAC degrader with a DC₅₀ of 0.00838 pM. SJ11646 has potent cytotoxicity against LCK-activated T-cell acute lymphoblastic leukemia (T-ALL) cells and primary leukemia samples with drastically prolonged suppression of LCK signaling, and induces T-ALL apoptosis. SJ11646 binds to 51 human kinases with a high affinity (particularly ABL1, KIT, and DDR1). SJ11646 has superior antileukemic efficacy in T-ALL mice model. . Pink: LCK ligand (HY-107447); Blue: CRBN ligase ligand (HY-163169); Black: linker (HY-76667)

HY-175261

DHI1	CDK Wee1 Checkpoint Kinase (Chk)	Cancer
DHI1 is an anti-leukemia agent with high selectivity for Jurkat (IC₅₀ = 21.83 μM) and HL-60 (IC₅₀ = 19.14 μM) leukemia cells and has low toxicity to non-cancerous cells. DHI1 can induce G2/M phase cell arrest in Jurkat and HL-60 leukemia cells, as well as S phase arrest in HL-60 cells, and has significant effects on cell cycle signaling molecules Wee1, cyclin B1, cdc2 on Tyr15, and Chk1. DHI1 inhibits the migration and invasion of Jurkat and HL-60 cells by disrupting cytoskeletal actin filaments. DHI1 can be used to study hematological malignancies .

HY-114648

AJI-9561	Bacterial	Infection Cancer
AJI-9561 is a benzoxazole derivative produced by Streptomyces sp. AJI-9561 exhibits cytotoxicity and antibacterial activity. AJI-9561 inhibits the proliferation of Jurkat T cells and mouse P388 leukemia cells, with its IC₅₀ being 0.88 and 1.63 μM respectively. AJI-9561 can be used for research on anti-cancer and antibacterial properties .

HY-177786

CDK12 ligand-3	Molecular Glues CDK	Cancer
CDK12 ligand-3 is a molecular glucose degrading agent that targets the CDK12 protein (DC₅₀ = 35 nM). CDK12 ligand-3 degrades CDK12, CDK13 and their regulatory subunit Cyclin K in a concentration dependent manner, and inhibits RNA polymerase II CTD (Ser2) phosphorylation. CDK12 ligand-3 exhibits potent anti proliferative activity against Jurkat cells. CDK12 ligand-3 can be used for research on cancers such as leukemia .

HY-178485

SJY26	PI3K HDAC Akt Histone Methyltransferase	Cancer
SJY26 is a PI3K/HDAC dual-target inhibitor with IC₅₀s of 0.59 nM (PI3Kα and PI3Kδ), 2.02 nM (PI3Kγ), 12.69 nM (PI3Kβ) and 114 nM (HDAC1). SJY26 exhibits potent broad-spectrum anti-proliferative activity, and is particularly sensitive to Jurkat and PC9R cells. SJY26 inhibited the migration of PC9R cells, arrested the cell cycle and induced cell apoptosis. SJY26 reduces AKT phosphorylation, and decreases histone H3 deacetylation (Ac-H3). SJY26 can be used for the studies of non-small cell lung cancer and leukemia .

HY-170814

G-quadruplex ligand 3	G-quadruplex	Cancer
G-quadruplex ligand 3 (Compound 16) is a G-quadruplex ligand with anticancer effects that chelate iron. G-quadruplex ligand 3 stabilizes G-quadruplexes in human leukemia Jurkat cells. G-quadruplex ligand 3 localizes in the cell nucleus, serving as a fluorescent nuclear tracer for the labile iron pool .

HY-W965550

Apoptosis inducer 40	Apoptosis	Cancer
Apoptosis inducer 40 is an apoptosis inducer. Apoptosis inducer 40 exhibits potent cytotoxic effects against jurkat and NB4 cells with IC₅₀ values of 4.5 μM and 3.6μM. Apoptosis inducer 40 induces apoptosis and arrests cell cycle. Apoptosis inducer 40 can be used for the research of cancer, such as acute myeloid leukemia (AML) .

HY-P11019

IS4	CXCR Calcium Channel	Cancer
IS4 is a selective CXCR4 competitive antagonist, with an IC₅₀ of 0.65 nM in THP-1 cells and 38.75 nM in Jurkat cells. IS4 is stable in serum and non-cytotoxic. IS4 competitively binds to CXCR4 with CXCL12, thereby inhibiting CXCL12-induced intracellular Ca ²⁺ release and cancer cell migration. IS4 can be used in the research on the prevention of metastasis of breast cancer, prostate cancer, leukemia, and other diseases .

HY-178459

PROTAC HPK1 Degrader-6	PROTACs MAP4K	Cancer
PROTAC HPK1 Degrader-6 (314) is a highly efficient and effective PROTAC degrader targeting HPK1 (IC₅₀ ＜ 50 nM). PROTAC HPK1 Degrader-6 can be used for the study of leukemia. Red: HPK1 ligand (HY-179196); Blue: E3 ligase CRBN ligand (HY-179197) .

HY-161335

HPK1-IN-43	MAP4K Interleukin Related IFNAR	Cancer
HPK1-IN-43 (compound 9f) is a HPK1 kinase inhibitor with the IC₅₀ value of 0.32 nM. HPK1-IN-43 inhibits the phosphorylation of the downstream protein SLP-76 and enhances the secretion of interleukin-2 (IL-2) and interferon-γ (IFN-γ). HPK1-IN-43 can be used in cancer research .

HY-151426

Anticancer agent 83	Apoptosis	Cancer
Anticancer agent 83 is a potent anticancer agent, inhibits LOX IMVI cells growth with a GI₅₀ value of 0.15 mM. Anticancer agent 83 reduces mitochondrial membrane potential and induces DNA damage to induces leukemia cells apoptosis .

HY-169318

DGKζ-IN-7	DGK Interleukin Related	Inflammation/Immunology Cancer
DGKζ-IN-7 (compound 97) is an oral active DGKζ inhibitor with the IC₅₀ of 33.4 nM. DGKζ-IN-6 inhibits the secretion of IL-2 and can be used for study of cancer and autoimmune diseases .

HY-169317

DGKζ-IN-6	DGK Interleukin Related	Inflammation/Immunology Cancer
DGKζ-IN-6 (compound 40) is an oral active DGKζ inhibitor with the IC₅₀ of 45.5 nM. DGKζ-IN-6 inhibits the secretion of IL-2 and can be used for study of cancer and autoimmune diseases .

HY-125542

DCZ3301	Apoptosis JAK STAT ERK PI3K Akt	Cancer
DCZ3301 is an apoptosis inducer. DCZ3301 modulates JAK2/STAT3, ERK1/2, and PI3K/AKT pathways. DCZ3301 induces G2/M and M phase cell cycle arrest and inhibits cell proliferation and viability. DCZ3301 enhances DNA damage, inhibits DNA repair, and suppresses angiogenesis. DCZ3301 can be used for the research of diffuse large B-cell lymphoma, multiple myeloma and leukemia/lymphoma .

HY-N0990

1,5,15-Trimethylmorindol	Others	Cancer
1,5,15-Trimethylmorindol is an anthraquinone isolated from the leaves of Morinda citrifolia. 1,5,15- trimethylmorindol (25 μg/mL) does not show significant cytotoxic activity on the human T-cell leukemia cell line, Jurkat, by itself but it shows cytotoxicity (IC₅₀ 14.5-15.0 μg/mL) when combined with 0.5-1.5 μg/mL of TRAIL in the cell proliferation assay .

HY-180782

Triphenyltin(IV) diisopropyl dithiocarbamate	DNA/RNA Synthesis Reactive Oxygen Species (ROS) Caspase Apoptosis	Cancer
Triphenyltin(IV) diisopropyl dithiocarbamate (Compound OC2) is an anti-leukemia agent. Triphenyltin(IV) diisopropyl dithiocarbamate exhibits extremely strong cytotoxicity towards Jurkat cells, with an IC₅₀ value of 0.1 μM. Triphenyltin(IV) diisopropyl dithiocarbamate causes DNA damage, which subsequently leads to mitochondrial dysfunction, a large amount of ROS production, and ultimately results in the activation of the mitochondrial apoptosis pathway (involving the activation of Caspase-9/-3) and the G0/G1 phase cell cycle arrest, all of which jointly lead to the death of leukemia cells .

HY-179372

Tubulin polymerization-IN-84	Microtubule/Tubulin Apoptosis	Cancer
Tubulin polymerization-IN-84 inhibits tubulin polymerization by targeting the colchicine-binding pocket, with anIC₅₀ = 10.9 μM. Tubulin polymerization-IN-84 shows antiproliferative activity against Jurkat, B16-F10, HCT116, and MDA-MB-231 cells (IC₅₀ = 60 nM, 380 nM, 138 nM, and 1.054 μM). Tubulin polymerization-IN-84 induces G2/M-phase arrest and apoptosis in B16-F10 cells. Tubulin polymerization-IN-84 suppresses tumor growth in a B16-F10 melanoma model and potentiates anti-tumor immunity in combination with a PD-L1 mAb for the research of T-cell acute lymphoblastic leukemia, melanoma, colon cancer, and breast cancer.

HY-181653

PROTAC SKP2 Degrader-1	PROTACs E1/E2/E3 Enzyme DNA/RNA Synthesis JAK STAT Apoptosis	Cancer
PROTAC SKP2 Degrader-1 is a PROTAC degrader targeting SKP2, with a K_d value of 6.28 μM. PROTAC SKP2 Degrader-1 induces targeted degradation of SKP2 via the ubiquitin-proteasome system. PROTAC SKP2 Degrader-1 stabilizes the expression of SOCS1 and regulates the expression of immunoproteasomes through the JAK/STAT pathway, thereby inhibiting tumor cell proliferation. PROTAC SKP2 Degrader-1 is applicable for cancer-related research .

HY-P992439

PF-06747143	CXCR	Cancer
PF-06747143 is recombinant anti-human antibody targeting CXCR4. PF-06747143 blocks CXCL12-induced calcium flux, F-actin polymerization, chemotaxis, cell migration, and leukemic cell bone marrow homing. PF-06747143 reduces tumor burden and improves survival in mouse models of hematologic malignancies. PF-06747143 can be used for the research of chronic lymphocytic leukemia, acute myeloid leukemia, and hematologic malignancies .

HY-181678

DNA-PK/HDAC6-IN-1	DNA-PK HDAC Apoptosis Mitochondrial Metabolism DNA/RNA Synthesis	Cancer
DNA-PK/HDAC6-IN-1 is a selcetive and orally active dual DNA-PK and HDAC6 inhibitor with IC₅₀ values of 84.2 and 64.8 nM. DNA-PK/HDAC6-IN-1 suppresses cancer cells proliferation, induces cancer cell cycle G2/M arrest, apoptosis, and decreases the mitochondrial membrane potential. DNA-PK/HDAC6-IN-1 induces DNA damage and elevates γ-H2AX levels. DNA-PK/HDAC6-IN-1 exhibits antitumor efficacy in AML animal mouse model. DNA-PK/HDAC6-IN-1 can be used for the research of acute myeloid leukemia .

HY-182550

Indoluidin D	Dihydroorotate Dehydrogenase	Cancer
Indoluidin D is a selective dihydroorotate dehydrogenase (DHODH) inhibitor with a human DHODH IC₅₀ of 210 nM. Indoluidin D selectively inhibits human DHODH activity, with induced effects rescuable by orotic acid. Indoluidin D promotes myeloid differentiation and inhibits cancer cell proliferation. Indoluidin D can be used for the research of acute promyelocytic leukemia .

HY-181869

PROTAC BET Degrader-17	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
PROTAC BET Degrader-17 is a potent BET protein PROTAC degrader. By recruiting the VHL E3 ligase, PROTAC BET Degrader-17 specifically degrades BRD2, BRD3 (DC₅₀=0.09 nM) and BRD4 (IC₅₀=4.3 nM). PROTAC BET Degrader-17 exhibits strong anti-tumor activity in acute myeloid leukemia (AML) studies; it not only inhibits cancer cell proliferation, induces cell cycle arrest and apoptosis, but also effectively suppresses tumor growth in xenograft mouse models. PROTAC BET Degrader-17 can be used to explore targeted therapies for acute myeloid leukemia .

HY-181867

PROTAC BET Degrader-16	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
PROTAC BET Degrader-16 (Compound A10) is a BET PROTAC degrader with a DC₅₀ of 0.31 nM against BRD4, and it preferentially targets BRD4 over other BET family members. PROTAC BET Degrader-16 degrades BRD2, BRD3 and BRD4 via the ubiquitin-proteasome system, a process that requires target binding and recruitment of the CRBN E3 ligase. PROTAC BET Degrader-16 induces cell cycle arrest and promotes apoptosis. PROTAC BET Degrader-16 exerts anti-tumor activity against acute myeloid leukemia .

HY-183555

MS108	PROTACs Epigenetic Reader Domain	Cancer
MS108 is a selective VHL-based eleven-nineteen leukemia protein (ENL) PROTAC degrader with DC₅₀ of 0.6 nM. MS108 recruits VHL E3 ligase to induce ENL degradation in a VHL- and ubiquitin-proteasome system (UPS)-dependent manner. MS108 degrades the ENL paralog AF9, which shares a highly conserved YEATS domain with ENL. MS108 suppresses proliferation of cancer cells .

HY-183077

BRD4 degrader-7	Epigenetic Reader Domain Molecular Glues	Cancer
BRD4 degrader-7 (Compound ZZ1) is a CTLH-dependent BRD4 degrader and c-Glue with a DC₅₀ of 489 nM. BRD4 degrader-7 converts to a sulfinic acid derivative inside cells, interacts with the basic pocket of YPEL5, mediates the bridging of BRD4 BD1 to the YPEL5 subunit of the CTLH E3 ubiquitin ligase, and thereby promotes the formation of a ternary complex. BRD4 degrader-7 can be used in research on Ewing's sarcoma and leukemia .

HY-182374

AX8819	Dipeptidyl Peptidase Apoptosis	Cancer
AX8819 is a selective dipeptidyl peptidase II (DPP II) inhibitor with an IC₅₀ of 0.88 nM. AX8819 induces caspase-dependent apoptosis. AX8819 exhibits low non-specific toxicity toward proliferating T cells. AX8819 can be used for the research of B cell chronic lymphocytic leukemia .

HY-111165

SNX-7081	HSP NF-κB ERK JNK PDGFR c-Myc DNA/RNA Synthesis Apoptosis	Inflammation/Immunology Cancer
SNX-7081 is an Hsp90 inhibitor with K_i and IC₅₀ values of 26 nM and 44 nM, respectively. SNX-7081 blocks the nuclear translocation of NF-κB, inhibits the production of pro-inflammatory cytokines, attenuates the ERK/JNK and PDGF signaling pathways, and suppresses LPS (HY-D1056)-induced nitric oxide production. SNX-7081 inhibits DNA repair, induces G₂/M cell cycle arrest, and triggers apoptosis via downregulation of MYC/nucleolin and activation of Fas. SNX-7081 can be used in research related to rheumatoid arthritis and cancer .

HY-112448

Lck-IN-6	Src Interleukin Related	Inflammation/Immunology
Lck-IN-6 (Compound 12g) is a Lck inhibitor with an IC₅₀ of 3 nM. Lck-IN-6 inhibits the production of IL-2. Lck-IN-6 can be used in the research of rheumatoid arthritis and inflammatory bowel disease .

HY-185459

PCIP-1	PARP Epigenetic Reader Domain	Cancer
PCIP-1 is a PARP2 inhibitor. PCIP-1 recruits BET proteins to PARP2 to inhibit DNA repair, acts via event-driven pharmacology, and does not inhibit PARP-catalyzed PARylation. PCIP-1 inhibits DNA repair, thereby inducing synthetic lethality in homologous recombination-deficient cancer cells and increasing the sensitivity of PARP1-knockout cells. PCIP-1 can be used in the research of homologous recombination-deficient cancers, T-cell acute lymphoblastic leukemia, and BRCA-mutant cancers .

HY-P991924

CO-1	CD47	Cancer
CO-1 is an IgG4 anti-CD47 antibody. CO-1 not only enhances themacrophage phagocytosis activity but also induces a unique and fast form of programmed celldeath (PCD) in cancer cells directly through ligation of CD47. CO-1 has anticancer activity against hematologic malignancies such as acute lymphoblastic leukemia .

HY-180416

TMC-169	Antibiotic	Cancer
TMC-169 is a potent antibiotic of the Aspochalasin group that can be isolated from Aspergillus flavipes. TMC-169 exhibits anti-tumor activity against multiple cancer cells. TMC-169 can be used for the research of cancer, such as hematologic malignancies, non-small cell lung cancer, breast cancer, and glioma .

Cat. No.	Product Name	Target	Research Area